What is known and objective: Ibrutinib is inhibiting the Bruton's tyrosine kinase (BTK), thereby influencing B-cell development. We describe an unexpected side effect of ibrutinib in two patients with chronic lymphocytic leukaemia concerning the vigorous decrease of two different diabetes-associated antibodies.
| WHAT IS KNOWN AND OBJECTIVE
The mechanism of action of ibrutinib is the blockade of Bruton's tyrosine kinase (BTK), thereby inhibiting an essential signalling pathway downstream of the B-cell receptor. Loss-of-function mutations of BTK, commonly referred to as X-linked agammaglobulinaemia, confirm its importance for regulation of development, homeostasis and survival of both normal and malignant B cells as well as immunoglobulin production. Ibrutinib has demonstrated efficacy as single-agent therapy in chronic lymphocytic leukaemia (CLL). The mild toxicity profile of the drug enables its continuous use over an extended period for the majority of patients. 1 We identified two patients with CLL and diabetes mellitus who experienced a remarkable side effect to ibrutinib. While patient A's chronic lymphocytic leukaemia was responding gradually to the drug, we observed that he was showing a simultaneous reduction in level of insulin antibodies which had developed during insulin therapy for type 2 diabetes. In patient B, we detected a substantial decline in glutamic acid decarboxylase autoantibodies (marker of type 1 diabetes and latent autoimmune diabetes in adults).
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| CASE DESCRIPTION

| Patient A
A 78-year-old male patient had been treated with diet and oral antidiabetic drugs for type 2 diabetes since 1990. Due to uncontrolled disease, therapy with twice-daily premixed insulin HumalogMix 25 (25% insulin lispro and 75% insulin lispro protamine suspension) was started in March 2010, and this was switched to NovoMix 70 (70% insulin aspart and 30% insulin aspart protamine suspension) and NovoMix30 (30% insulin aspart and 70% insulin aspart protamine suspension) 2 years later. Over the years, the insulin dose had to be adjusted upwards and the patient was put on pioglitazone to curb in- As there were no other changes in drugs or lifestyle, we suspected a causal relationship with ibrutinib when patient A reported recurrent hypoglycaemic events 2 weeks after onset of therapy. Five weeks after start of ibrutinib, he described a faster effect of injected insulin and a concomitant drop of his insulin requirement. In addition, he reported increased muscular fatigue particularly in the legs.
Within 11 weeks of ibrutinib treatment, patient A was able to lower his daily insulin dose by 30% (from 95 to 66 U of premixed insulin).
Insulin doses are listed in Table 1 . HbA 1c varied from 7.4% (57 mmol/ mol) to 6.4% (44 mmol/mol) and back to 7.3% (56 mmol/mol).
In November 2010, the first serum was routinely collected for CLL assessment, that is 8 months after insulin therapy had been started.
Insulin antibodies (IA) were already present (388 U/mL). At that time and later, neither glutamic acid decarboxylase (GAD) autoantibodies nor tyrosine phosphatase-related islet antigen-2 autoantibodies (IA2A)
were detectable ruling out latent autoimmune diabetes in adults (LADA) in patient A. All of these antibodies were measured in the sera of both patients before and during ibrutinib employing an ELISA (Orgentec®, four vaccine-induced antibody levels, only tetanus toxoid antibodies showed a profound but retarded decrease.
The starting point of our investigation was a previous report 6 on the special importance of BTK for supporting the activation and survival of autoreactive, murine, anti-insulin B cells. BTK deficiency protected non-obese mice from producing anti-insulin antibodies and the development of type 1 diabetes. 6 We speculate that the decrease of murine anti-insulin B cells following BTK inhibition 6 is mirrored by the rapid loss of insulin antibodies in patient A. It was hypothesized 6, 7 that targeting of BTK with ibrutinib might preferentially impair maturation and/or survival of autoimmune B lymphocytes while sparing the protective, polyclonal immunoglobulin repertoire. The disproportional decline of insulin antibody levels in contrast to vaccine-induced antibody levels ( Figure 1A ) supports this hypothesis. Our findings suggest that the insulin antibodies become preferentially produced by short-lived plasmablasts, while the vaccine-induced, high-affinity antibodies are the product of long-lived plasma cells, known to be independent of further B-cell receptor stimuli and thus BTK activity.
We note that a small dose of ibrutinib is sufficient to suppress insulin antibodies production in patient A as well as to control his CLL (results not shown). However, ibrutinib, nitrendipine, simvastatin (additional medication) and to a lesser extent pioglitazone are metabolized by CYP3A4.
When pioglitazone was stopped after 24 weeks, a prompt increase in insulin antibodies was detected as well as an increase in insulin requirement. After 3 weeks, pioglitazone was restarted and insulin antibody level decreased again (Table 1) . We assume that with pioglitazone withdrawal, faster clearance of ibrutinib lead to insufficient BTK inhibition.
| CASE DESCRIPTION
| Patient B
The 76-year-old male patient had been treated with diet and oral an- However, there is little data available from clinical trials in humans of ibrutinib in other autoimmune diseases. [8] [9] [10] [11] The nature of the antigen interacting with the B-cell receptor (large, multivalent antigens of high affinity versus small antigens of low affinity like insulin 6 and now GAD) seems to be of major relevance for the ibrutinib effect.
CYP3A activity can be influenced by a variety of rare variants in CYP3A4 and CYP3A5. However, for screening purposes, we selected two frequent variants (CYP3A4*22, CYP3A5*3) that have repeatedly been shown to have a major impact on the metabolism of various drugs including statins, tacrolimus, erythromycin (Appendix 1).
The mutation analysis of CYP3A4*22 rs35599367 and CYP3A5*3 rs776746 was performed using Light Cycler PCR/melting point analysis. Patients A and B are homozygous carriers of the loss-offunction CYP3A5*3 allele which is the major allele in Caucasians.
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The CYP3A4*22 allele with a frequency of 5-7% in the Caucasian population is associated with low hepatic CYP3A4 expression and activity. [13] [14] [15] This dysfunctional variant was not detected indicating that both patients are metabolizing the drug like the majority of Caucasians. Both patients are still taking 140 mg ibrutinib daily. The effective dose is obviously higher if given with other CYP3A4 substrates. A pharmacokinetic study comprising 56 patients with a variety of B-cell malignancies indicated full occupancy of the BTK active site, that is complete kinase inhibition, at doses of 2.5 mg/kg per day or more. 16 However, outside of clinical trials, the prescribed ibrutinib doses to CLL patients may vary between one tablet (140 mg) every 2-3 days and three tablets every day.
| WHAT IS NEW AND CONCLUSION
This is the first report of a patient with insulin antibodies and a second patient with GAD autoantibodies who showed marked decreases with ibrutinib therapy for CLL while total antibody levels were maintained in patient A. Our findings support the current view that the survival of autoreactive B cells depends on BTK to a greater degree than normal B cells. 10 Our cases reveal an unknown side effect of ibrutinib which could be useful for diabetic patients who show autoreactive B-cell responses. 
